A generic version of Otsuka Pharmaceutical's Myleran injection, or busulfan, will be launched in the US by partners Mylan and Aspen Pharmacare. The single-dose vial solution is indicated as a treatment for patients with chronic myelogenous leukemia, in combination with cyclophosphamide, as a conditioning regimen for those who will undergo allogeneic hematopoietic progenitor cell transplantation.
Generic Myleran injection to be launched in the US for leukemia patients
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.